<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157907">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01693393</url>
  </required_header>
  <id_info>
    <org_study_id>COLO400BDE02T</org_study_id>
    <nct_id>NCT01693393</nct_id>
  </id_info>
  <brief_title>Low Dose Cyclosporin A in Primary Sjögren Syndrome</brief_title>
  <acronym>CYPRESS</acronym>
  <official_title>A Phase II Pilot-Study With Low-dose Sandimmun Optoral (Cyclosporin A) for the Treatment of Primary Sjögren Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sandimmun optoral (Cyclosporin A) is used for the musculoskeletal manifestations of Primary
      Sjögren Syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NSAR are used currently for the treatment of musculoskeletal manifestations at Sjögren
      Syndrome for the symptomatic release of pain. For therapy-resistant cases drugs also used in
      Rheumatoid Arthritis are used. For these drugs there is no registration for the treatment of
      Sjögren Syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Examination of the therapeutic effects (improvement in number of tender, swolen joints, DAS 28) of low dose Cyclosporine A in patients with primary Sjögren Syndrome and articular involvement after a treatment-phase of 16 weeks.</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the safety (type and number of adverse events and serious adverse events) of low-dose Cyclosporine A in patients with primary Sjögren Syndrome</measure>
    <time_frame>28 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Study the general health changes and improvement of Sicca-symptoms</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Documentation of improvement of articular manifestations by ultrasound examination</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sjögren´s Syndrome</condition>
  <arm_group>
    <arm_group_label>Cyclosporine A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will receive Cyclosporine A in a dose of 2mg/kg/BW daily for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A</intervention_name>
    <description>Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period</description>
    <arm_group_label>Cyclosporine A</arm_group_label>
    <other_name>Sandimmun optoral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a primary Sjögren´s Syndrome

          -  Liver values above 1,5 ULN

          -  uncontrolled arterial hypertension

          -  intraarticular or systemic use of Glucocorticoids in the last 4 weeks before

          -  begin with Study medication

        Exclusion Criteria:

          -  pre-treatment with Cyclosporine A

          -  Infection

          -  Neoplasia

          -  relevant cardiac, pulmonary, neurologic or psychiatric disease

          -  life-Vaccination within 4 weeks before begin with study medication

          -  pregnant or breast-feeding

          -  weight under 45kg or more than 110kg
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugen Feist, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Universitätsklinikum Berlin Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>September 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Eugen Feist</investigator_full_name>
    <investigator_title>PD. Dr. med. Eugen Feist</investigator_title>
  </responsible_party>
  <keyword>primary Sjogren´s Syndrome</keyword>
  <keyword>Cyclosporine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
